Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317841 ↗At a glance
Journal article in PLOS ONE, 2025. Written by Basile Chrétien and 7 co-authors. Institution: Center for Advanced Medicine and Clinical Research, Section of Biostatistics, Nagoya University Graduate School of Medicine, Aichi, Japan. Major MEDLINE topics: Hypertension, Selective Serotonin Reuptake Inhibitors, Pharmacovigilance. 43 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Recent literature has reported instances of drug associated with hypertension with serotonin reuptake inhibitors (SRIs). Nonetheless, the association between SRIs and hypertension development is the subject of ongoing debate. It remains uncertain whether this is indicative of a class effect, and if dose-effect exist. To investigate the potential class effect associating SRIs with hypertension reporting, we utilized real-world data from VigiBase®, the World Health Organization (WHO) pharmacovigilance database.
Methods
We conducted an updated disproportionality analysis within VigiBase® to identify a signal of hypertension reporting with individual SRIs by calculating adjusted reporting odds ratios (aRORs) within a multivariate case/non-case study design. Additionally, we explored the presence of a dose-effect relationship.
Results
The database contained 13,682 reports of SRI associated with hypertension (2.2%), predominantly in women (70.0%). Hypertension was most reported in the 45-64 years old age group (44.8%). A total of 3,879 cases were associated with sertraline, 2,862 with fluoxetine, 2,516 with citalopram, 2,586 with escitalopram, 2,441 with paroxetine, 201 with fluvoxamine and 8 with zimeldine. A significant ROR was observed for all SRIs in both univariate (RORs ranging from 1.39 to 1.54) and multivariable analyses (aRORs ranging from 1.16 to 1.40) after adjustments for age group, sex, concurrent antihypertensive medication and drugs knowns to induce hypertension, except for fluvoxamine and zimeldine. No dose-response relationship was identified.
Conclusion
This investigation, conducted under real life conditions, unveils a notable pharmacovigilance safety signal associating SRI usage with hypertension reporting. No dose-response effect was detectable. Further longitudinal studies are warranted.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Center for Advanced Medicine and Clinical Research, Section of Biostatistics, Nagoya University Graduate School of Medicine, Aichi, Japan.
- Normandie Univ, UNICAEN, Department of general practice, Caen, France.
- CHU Caen, Pharmacology Department, Caen, France.
- Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Caen, France.
ORCID profiles: Basile Chrétien, Nishida Kazuki, Xavier Humbert
Cite
APA
Chrétien, B., Rabiaza, A., Kazuki, N., Fedrizzi, S., Sassier, M., Dolladille, C., Alexandre, J., & Humbert, X. (2025). Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency. PLOS ONE. https://doi.org/10.1371/journal.pone.0317841
Vancouver
Chrétien B, Rabiaza A, Kazuki N, Fedrizzi S, Sassier M, Dolladille C, et al. Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency. PLOS ONE. 2025. doi:10.1371/journal.pone.0317841
BibTeX
@article{Chrtien2025,
author = {Chrétien, Basile and Rabiaza, Andry and Kazuki, Nishida and Fedrizzi, Sophie and Sassier, Marion and Dolladille, Charles and Alexandre, Joachim and Humbert, Xavier},
title = {Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317841}
}
EUVIMED